Optimising therapy for insulin-treated type 2 diabetes mellitus

Drugs and Aging

Volumn 17, Issue 4, 2000, Pages 283-294

  Hermann, Leif Sparre ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

DIET; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; WEIGHT GAIN;

EID: 0033755513     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200017040-00004     Document Type: Review

References (66)

1. A desktop guide to type 2 diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
5. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
6. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
7. Therapeutic approaches to type 2 diabetes. Overview of current therapeutic options: Session summary
8. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus
9. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: A randomized controlled trial
10. Combination therapy with insulin and metformin
11. Pathogenesis of NIDDM
12. Pathogenesis of non-insulin-dependent diabetes mellitus
13. Glucose toxicity
14. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
15. Metformin investigator group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
16. Biguanides: Basic aspects and clinical uses
17. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: A double-blind controlled study
18. Reinitiation of oral hypoglycemic therapy: The Alabama experience
19. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VACSDM): Results of the feasibility trial
20. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: A randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group
21. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
22. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group
23. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes
24. Insulin analogues and their potential in the management of diabetes mellitus
25. NIDDM patients fears and hopes about insulin therapy-the basis of patients reluctance
26. Hyperinsulinemia as an independent risk factor for ischemic heart disease
27. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes
28. Combination therapy: Insulin-sulfonylurea and insulin-metformin
29. Clinical pharmacology of sulfonylureas
30. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus
31. Insulin plus a sulfonylurea agent for treating type 2 diabetes
32. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes: A meta-analysis of the randomized placebo-controlled trials
33. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A meta-analysis
34. Insulin and sulphonylurea in the therapy of type 2 diabetes
35. One-year response to evening insulin therapy in non-insulin-dependent diabetes
36. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: A 1-year follow-up
37. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients
38. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone: Glimepiride Combination Group
39. Metformin: A review of its metabolic effects
40. Clinical pharmacology of biguanides
41. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes
42. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors
43. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control
44. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
45. Evaluation of optimal therapy in type 2 diabetic patients insufficiently treated with sulfonylureas: The Austrian insulin intervention study
46. A risk-benefit assessment of metformin in type 2 diabetes mellitus
47. The use of metformin and oral sulfonylureas in type 2 diabetics previously managed on insulin or insulin and oral sulfonylureas
48. A randomized study of re-institution of oral antidiabetic agents in a managed care setting
49. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment
50. Overview of current therapeutic options in type 2 diabetes: Rationale for combining oral agents with insulin therapy
51. Troglitazone-antihyperglycemic activity and potential role in the treatment of type 2 diabetes
52. Troglitazone use in insulin-treated type 2 diabetic patients
53. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus
54. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
55. Thiazolidinediones for type 2 diabetes: New agents reduce insulin resistance but need long term clinical trials
56. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial
57. A double-blind placebo controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type 2 diabetes
58. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes
59. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment
60. Management of non-insulin-dependent diabetes mellitus in Europe: A consensus view
61. Efficacy of bedtime NPH insulin alone, as compared to combination with metformin and/or glipizide in NIDDM patients with secondary failure to oral hypoglycemic agents
62. The use of insulin alone and in combination with oral agents in type 2 diabetes
63. Oral antihyperglycaemics: Considerations in older patients with non-insulin-dependent diabetes mellitus